Edition:
India

Alector Inc (ALEC.OQ)

ALEC.OQ on NASDAQ Stock Exchange Global Select Market

14.85USD
7 Aug 2020
Change (% chg)

$-0.31 (-2.04%)
Prev Close
$15.16
Open
$15.08
Day's High
$15.89
Day's Low
$14.53
Volume
319,934
Avg. Vol
255,550
52-wk High
$35.93
52-wk Low
$13.65

Latest Key Developments (Source: Significant Developments)

Alector Says Orbimed Advisors Cuts Share Stake In Co To 3.5% From 7.0%
Friday, 17 Jul 2020 

July 16 (Reuters) - Alector Inc ::ORBIMED ADVISORS LLC CUTS SHARE STAKE IN ALECTOR INC TO 3.5% AS OF JULY 14 FROM A STAKE OF 7.0% AS OF JULY 7 - SEC FILING.  Full Article

Alector Inc Files Amendment Registration Statement For Public Offering Of 7 Million Shares Of Common Stock
Wednesday, 29 Jan 2020 

Jan 29 (Reuters) - Alector Inc ::ALECTOR INC FILES AMENDMENT REGISTRATION STATEMENT FOR PUBLIC OFFERING OF 7 MILLION SHARES OF COMMON STOCK – SEC FILING.  Full Article

Alector Announces Proposed Public Offering Of Common Stock
Tuesday, 28 Jan 2020 

Jan 27 (Reuters) - Alector Inc ::ALECTOR ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ALECTOR INC QUARTERLY INTENDS TO OFFER 5.1 MILLION SHARES OF ITS COMMON STOCK.  Full Article

Alector Reports Qtrly Loss Per Share $0.36
Tuesday, 13 Aug 2019 

Aug 12 (Reuters) - Alector Inc ::ALECTOR REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2019 FINANCIAL RESULTS.ALECTOR INC - ENDED QUARTER WITH $411 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.ALECTOR INC - COLLABORATION REVENUE FOR Q2 OF 2019 WAS $6.9 MILLION COMPARED TO $7.1 MILLION FOR SAME PERIOD IN 2018.ALECTOR INC- QTRLY LOSS PER SHARE $0.36.  Full Article

Alector Announces Data From On-Going Early-Stage AL001 Trial
Thursday, 18 Jul 2019 

July 17 (Reuters) - Alector Inc ::ALECTOR ANNOUNCES DATA FROM ON-GOING PHASE 1B TRIAL DEMONSTRATING THAT AL001 REVERSES PROGRANULIN DEFICIENCY IN FRONTOTEMPORAL DEMENTIA PATIENTS.ALECTOR INC - INITIAL POSITIVE DATA FROM A SUBSET OF PATIENTS IN COMPANY'S INFRONT CLINICAL STUDY OF ITS PRODUCT CANDIDATE, AL001.ALECTOR INC - PHASE 2 CLINICAL TRIAL IN FTD-GRN PATIENTS IS EXPECTED TO START IN SECOND HALF OF 2019.ALECTOR INC - BASED ON INITIAL FINDINGS IN INFRONT CLINICAL STUDY, AL001 WAS SEEN TO BE GENERALLY SAFE & WELL-TOLERATED UP TO HIGHEST DOSE LEVEL.  Full Article

Alector Posts Qtrly Loss Per Share Of $0.42
Tuesday, 14 May 2019 

May 13 (Reuters) - Alector Inc ::ALECTOR REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 REVENUE $5.6 MILLION VERSUS $4.9 MILLION.FOR Q1 OF 2019, ALECTOR REPORTED A NET LOSS OF $18.6 MILLION, COMPARED TO A NET LOSS OF $8.4 MILLION.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $436.6 MILLION AS OF MARCH 31, 2019.QTRLY LOSS PER SHARE $0.42.  Full Article

Orbimed Advisors LLC Reports 18.86 Percent Stake In Alector Inc As Of Feb 11 - SEC Filing
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - OrbiMed Advisors LLC::ORBIMED ADVISORS LLC REPORTS 18.86 PERCENT STAKE IN ALECTOR INC AS OF FEB 11 - SEC FILING.ORBIMED ADVISORS LLC SAYS SHARES OF ALECTOR WERE ACQUIRED FOR PURPOSE OF MAKING AN INVESTMENT.ORBIMED ADVISORS SAYS SHARES OF ALECTOR WERE ACQUIRED NOT WITH INTENTION OF ACQUIRING CONTROL OF BUSINESS ON BEHALF OF ITS ADVISORY CLIENTS.  Full Article

Alector Announces Pricing Of Initial Public Offering
Thursday, 7 Feb 2019 

Feb 6 (Reuters) - Alector Inc ::ALECTOR ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING OF 9.25 MILLION SHARES OF COMMON STOCK TO PUBLIC AT $19.00 PER SHARE.  Full Article